Healthcare: Digging Into Disappointment. What Investors Need To Know About Sarepta and Gilead Sciences' "Bad News"

<div id="divtagdefaultwrapper"> <p><span style="color: #000000;">Discussing the details behind the FDA's negative vote on Sarepta's DMD drug and Gilead Sciences' sliding hepatitis C sales.</span></p> </div>